+41 91 682 20 40 info@elixi-int.com

ABOUT US

We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.

 

QUALITY

As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more

 

WHO WE ARE

We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.

 

NEWS

Forxiga and Edistride (Dapagliflozin) recommended by EMA as first oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of…

read more

Cablivi (caplacizumab-yhdp) approved by FDA for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)

The U.S. Food and Drug Administration has approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma…

read more

First generic version of Sabril ( vigabatrin) approved by FDA for the treatment of complex partial seizures

The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex…

read more

Ultomiris (ravulizumab), approved by FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)

The U.S. Food and Drug Administration has approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal…

read more

European Commission Approves Merck’s DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen for the Treatment of HIV-1 in Appropriate Patients

Delstrigo is an antiviral medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that…

read more

FDA approves Elzonris (tagraxofusp-erzs), first treatment for rare blood disease

The U.S. Food and Drug Administration has approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm…

read more

FDA approves Xospata ( gilteritinib) for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation

The U.S. Food and Drug Administration has approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed…

read more

FDA approves Firdapse (amifampridine), first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder

The U.S. Food and Drug Administration has approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in…

read more

FDA approves Vitrakvi (larotrectinib), an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor.

The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients…

read more

Alunbrig ( brigatinib) approved by EMA for a specific group of lung cancer patients

Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell…

read more

FDA approves Daurismo (glasdegib) new treatment for patients with acute myeloid leukemia

The U.S. Food and Drug Administration has approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC),…

read more

Fexinidazole, first oral-only medicine for the treatment of human African trypanosomiasis (HAT), recommended for approval.

EMA’s human medicines committee has adopted a positive opinion for Fexinidazole Winthrop (fexinidazole), the first oral-only medicine (tablets) for the…

read more

CONTACT US

ELIXI International SA

 

Vicolo Oldelli 1
6830 Chiasso / Switzerland

Tel./Fax +41 91 6822040

Your name (required)

Your e-mail (required)

Your message